| Ident. | Authors (with country if any) | Title |
|---|
| 000005 (2020) |
Tadeusz Płusa | [Options for controlling new Corona virus infection - 2019-nCoV]. |
| 000012 (2020) |
Seoyoung C. Kim [États-Unis] ; Sebastian Schneeweiss [États-Unis] | When Randomized Clinical Trials and Real-World Evidence Say the Same: Tocilizumab and Its Cardiovascular Safety. |
| 000020 (2020) |
Jared Radbel [États-Unis] ; Navaneeth Narayanan [États-Unis] ; Pinki J. Bhatt [États-Unis] | Use of tocilizumab for COVID-19 infection-induced cytokine release syndrome: A cautionary case report. |
| 000035 (2020) |
Limin Li [République populaire de Chine] ; Jie Liu [République populaire de Chine] ; Mengyuan Xu [République populaire de Chine] ; Hongjuan Yu [République populaire de Chine] ; Chengfang Lv [République populaire de Chine] ; Fenglin Cao [République populaire de Chine] ; Zhenkun Wang [République populaire de Chine] ; Yueyue Fu [République populaire de Chine] ; Mingwen Zhang [République populaire de Chine] ; Hongbin Meng [République populaire de Chine] ; Xiaoqian Zhang [République populaire de Chine] ; Liqing Kang [République populaire de Chine] ; Zhuo Zhang [République populaire de Chine] ; Jinmei Li [République populaire de Chine] ; Jiawei Feng [République populaire de Chine] ; Xin Lian [République populaire de Chine] ; Lei Yu [République populaire de Chine] ; Jin Zhou [République populaire de Chine] | Treatment response, survival, safety, and predictive factors to chimeric antigen receptor T cell therapy in Chinese relapsed or refractory B cell acute lymphoblast leukemia patients |
| 000042 (2020) |
Prakhar Vijayvargiya [États-Unis] ; Zerelda Esquer Garrigos [États-Unis] ; Natalia E. Castillo Almeida [États-Unis] ; Pooja R. Gurram [États-Unis] ; Ryan W. Stevens [États-Unis] ; Raymund R. Razonable [États-Unis] | Treatment Considerations for COVID-19: A Critical Review of the Evidence (or Lack Thereof) |
| 000076 (2020) |
Philip George [Nouvelle-Zélande] ; Nathaniel Dasyam [Nouvelle-Zélande] ; Giulia Giunti [Nouvelle-Zélande] ; Brigitta Mester [Nouvelle-Zélande] ; Evelyn Bauer [Nouvelle-Zélande] ; Bethany Andrews [Nouvelle-Zélande] ; Travis Perera [Nouvelle-Zélande] ; Tess Ostapowicz [Nouvelle-Zélande] ; Chris Frampton [Nouvelle-Zélande] ; Peng Li [République populaire de Chine] ; David Ritchie [Australie] ; Catherine M. Bollard [États-Unis] ; Ian F. Hermans [Nouvelle-Zélande] ; Robert Weinkove [Nouvelle-Zélande] | Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE) |
| 000082 (2020) |
Eun-Jung Park [Corée du Sud] ; Hyungjin Kim [Corée du Sud] ; Seung Min Jung [Corée du Sud] ; Yoon-Kyoung Sung [Corée du Sud] ; Han Joo Baek [Corée du Sud] ; Jisoo Lee [Corée du Sud] | The use of biological disease-modifying antirheumatic drugs for inflammatory arthritis in Korea: results of a Korean Expert Consensus |
| 000091 (2020) |
Guillaume Decarriere [France] ; Thomas Barnetche [France] ; Bernard Combe [France] ; Cécile Gaujoux-Viala [France] ; Cédric Lukas [France] ; Jacques Morel [France] ; Claire Daien [France] | The most appropriate conventional DMARD to combine with different advanced therapies in rheumatoid arthritis: a systematic literature review with meta-analysis. |
| 000141 (2020) |
Adam Amlani [Canada] ; Claire Barber [Canada] ; Aurore Fifi-Mah [Canada] ; Jose Monzon [Canada] | Successful Treatment of Cytokine Release Syndrome with IL-6 Blockade in a Patient Transitioning from Immune-Checkpoint to MEK/BRAF Inhibition: A Case Report and Review of Literature. |
| 000143 (2020) |
Eduardo Mysler [Argentine] ; Mario H. Cardiel [Mexique] ; Ricardo M. Xavier [Brésil] ; Alejandra L Pez ; Allan Ramos-Esquivel [Costa Rica] | Subcutaneous Tocilizumab in Monotherapy or in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Latin American Patients With Moderate to Severe Active Rheumatoid Arthritis: A Multicenter, Phase IIIb Study. |
| 000162 (2020) |
Alexandre Sepriano [Oman] ; Andreas Kerschbaumer [Autriche] ; Josef S. Smolen [Autriche] ; Désirée Van Der Heijde [Pays-Bas] ; Maxime Dougados [France] ; Ronald Van Vollenhoven [Pays-Bas] ; Iain B. Mcinnes [Royaume-Uni] ; Johannes W. Bijlsma [Pays-Bas] ; Gerd R. Burmester [Allemagne] ; Maarten De Wit [Suisse] ; Louise Falzon [États-Unis] ; Robert Landewé [Pays-Bas] | Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. |
| 000163 (2020) |
Jacques Morel [France] ; Marie Locci [France] ; Frédéric Banal [France] ; Bernard Combe [France] ; Grégoire Cormier [France] ; Maxime Dougados [France] ; René-Marc Flipo [France] ; Christian Marcelli [France] ; Thao Pham [France] ; Stéphanie Rist [France] ; Elizabeth Solau Gervais [France] ; Jean Sibilia [France] ; Cédric Lukas [France] | Safety of surgery in patients with rheumatoid arthritis treated with tocilizumab: data from the French (REGistry -RoAcTEmra) Regate registry. |
| 000164 (2020) |
Giulia Cassone ; Andreina Manfredi ; Fabiola Atzeni ; Vincenzo Venerito ; Caterina Vacchi ; Valentina Picerno ; Federica Furini ; Gian Luca Erre ; Paola Tomietto ; Anna Laura Fedele [Italie] ; Giovanni Della Casa [Italie] ; Valeria Nucera ; Chiara Giannitti [Italie] ; Carlo Salvarani ; Marco Sebastiani | Safety of Abatacept in Italian Patients with Rheumatoid Arthritis and Interstitial Lung Disease: A Multicenter Retrospective Study |
| 000165 (2020) |
Chao Zhang [République populaire de Chine] ; Meini Zhang [République populaire de Chine] ; Wei Qiu [République populaire de Chine] ; Hongshan Ma [République populaire de Chine] ; Xinghu Zhang [République populaire de Chine] ; Zilong Zhu [République populaire de Chine] ; Chun-Sheng Yang [République populaire de Chine] ; Dongmei Jia [République populaire de Chine] ; Tian-Xiang Zhang [République populaire de Chine] ; Meng Yuan [République populaire de Chine] ; Yan Feng [République populaire de Chine] ; Li Yang [République populaire de Chine] ; Wenli Lu [République populaire de Chine] ; Chunshui Yu [République populaire de Chine] ; Jeffrey L. Bennett [États-Unis] ; Fu-Dong Shi [République populaire de Chine] | Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial. |
| 000166 (2020) |
Elyes Bouajina [Tunisie] ; Leith Zakraoui [Tunisie] ; Montassar Kchir [Tunisie] ; Samir Kochbati [Tunisie] ; Sofiene Baklouti [Tunisie] | Safety and efficacy of tocilizumab as monotherapy or in combination with methotrexate in Tunisian patients with active rheumatoid arthritis and inadequate response to disease-modifying anti-rheumatic drugs in conditions close to clinical practice. |
| 000167 (2020) |
Peter A. Riedell ; Michael R. Bishop | Safety and efficacy of axicabtagene ciloleucel in refractory large B-cell lymphomas |
| 000168 (2020) |
Tsutomu Takeuchi [Japon] ; Yoshiya Tanaka [Japon] ; Sakae Tanaka [Japon] ; Atsushi Kawakami [Japon] ; Yeong-Wook Song [Corée du Sud] ; Yi-Hsing Chen [Taïwan] ; Mitsuhiro Rokuda [Japon] ; Hiroyuki Izutsu [Japon] ; Satoshi Ushijima [Japon] ; Yuichiro Kaneko [Japon] ; Yoshihiro Nakashima [Japon] ; Teruaki Shiomi [Japon] ; Emi Yamada [Japon] | Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan |
| 000169 (2020) |
Maria Antonietta Barbieri [Italie] ; Giuseppe Cicala [Italie] ; Paola Maria Cutroneo [Italie] ; Elisabetta Gerratana [Italie] ; Caterina Palleria [Italie] ; Caterina De Sarro [Italie] ; Ada Vero [Italie] ; Luigi Iannone [Italie] ; Antonia Manti [Italie] ; Emilio Russo [Italie] ; Giovambattista De Sarro [Italie] ; Fabiola Atzeni [Italie] ; Edoardo Spina [Italie] | Safety Profile of Biologics Used in Rheumatology: An Italian Prospective Pharmacovigilance Study. |
| 000223 (2020) |
Chih-Chia Lu [République populaire de Chine] ; Mei-Yu Chen [République populaire de Chine] ; Yuh-Lih Chang | Potential therapeutic agents against COVID-19: What we know so far |
| 000237 (2020) |
Zaid H. Temrikar [États-Unis] ; Satyendra Suryawanshi [États-Unis] ; Bernd Meibohm [États-Unis] | Pharmacokinetics and Clinical Pharmacology of Monoclonal Antibodies in Pediatric Patients |
| 000247 (2020) |
Gabriella Giancane [Italie] ; Joost F. Swart [Pays-Bas] ; Elio Castagnola [Italie] ; Andreas H. Groll [Allemagne] ; Gerd Horneff [Allemagne] ; Hans-Iko Huppertz [Allemagne] ; Daniel J. Lovell [États-Unis] ; Tom Wolfs [Pays-Bas] ; Troels Herlin [Danemark] ; Pavla Dolezalova [République tchèque] ; Helga Sanner [Norvège] ; Gordana Susic [Serbie] ; Flavio Sztajnbok [Brésil] ; Despoina Maritsi [Grèce] ; Tamas Constantin [Hongrie] ; Veronika Vargova [Slovaquie] ; Sujata Sawhney [Inde] ; Marite Rygg [Norvège] ; Sheila K. Oliveira [Brésil] ; Marco Cattalini [Italie] ; Francesca Bovis [Italie] ; Francesca Bagnasco [Italie] ; Angela Pistorio [Italie] ; Alberto Martini [Italie] ; Nico Wulffraat [Pays-Bas] ; Nicolino Ruperto [Italie] | Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee |
